Cystectomy in Metastatic Bladder Cancer: Feasibility, Safety and Outcomes
The benefits of cystectomy in mBCa setting are mainly hidden by QoL improvement and the decreasing number of the potential contraindications to the systemic therapy. Potential effects that reduce adverse events during chemotherapy should prompt to estimate oncological preferences of cystectomy in advanced bladder cancer.
Authors
- D. Koshel
- S. Semko (ORCID: https://orcid.org/0000-0002-1657-5752)
- О. Кононенко (ORCID: https://orcid.org/0000-0001-7733-9051)
- O. Buyvol
- O. Stakhovsky
- B. Hrechko
- O. Voylenko (ORCID: https://orcid.org/0000-0003-3781-3622)
- M. Pikul (ORCID: https://orcid.org/0000-0003-1590-235X)
- E.O. Stakhovsky
- Andriy TYMOSHENKO
- U. Vitruk
Institutions
- National Cancer Institute (UA)
Publication Details
- Journal
- Experimental Oncology
- Published
- 2025-02-20
- DOI
- https://doi.org/10.15407/exp-oncology.2024.04.345
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00